- Home
- HSII vs PRTA Comparison
HSII vs PRTA Comparison
Compare HSII & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- PRTA
- Stock Information
- Founded
- HSII 1953
- PRTA 2012
- Country
- HSII United States
- PRTA Ireland
- Employees
- HSII N/A
- PRTA N/A
- Industry
- HSII Diversified Commercial Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- PRTA Health Care
- Exchange
- HSII Nasdaq
- PRTA Nasdaq
- Market Cap
- HSII 931.5M
- PRTA 802.8M
- IPO Year
- HSII 1999
- PRTA N/A
- Fundamental
- Price
- HSII $46.05
- PRTA $12.91
- Analyst Decision
- HSII Buy
- PRTA Buy
- Analyst Count
- HSII 2
- PRTA 7
- Target Price
- HSII $46.00
- PRTA $57.67
- AVG Volume (30 Days)
- HSII 135.1K
- PRTA 448.2K
- Earning Date
- HSII 11-04-2024
- PRTA 11-12-2024
- Dividend Yield
- HSII 1.32%
- PRTA N/A
- EPS Growth
- HSII N/A
- PRTA N/A
- EPS
- HSII 1.83
- PRTA N/A
- Revenue
- HSII $1,075,544,000.00
- PRTA $133,350,000.00
- Revenue This Year
- HSII $7.80
- PRTA $46.28
- Revenue Next Year
- HSII $2.89
- PRTA N/A
- P/E Ratio
- HSII $24.92
- PRTA N/A
- Revenue Growth
- HSII 6.55
- PRTA N/A
- 52 Week Low
- HSII $26.52
- PRTA $12.31
- 52 Week High
- HSII $49.02
- PRTA $41.55
- Technical
- Relative Strength Index (RSI)
- HSII 52.92
- PRTA 43.50
- Support Level
- HSII $44.55
- PRTA $12.31
- Resistance Level
- HSII $46.04
- PRTA $14.28
- Average True Range (ATR)
- HSII 1.16
- PRTA 0.98
- MACD
- HSII -0.28
- PRTA 0.00
- Stochastic Oscillator
- HSII 32.20
- PRTA 33.73
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).